Metastatic breast cancer country reports

Despite great improvements in diagnosis and treatment, breast cancer remains the most frequent cause of cancer death in women worldwide. 

Context

More than 500,000 women die from breast cancer every year. Metastatic breast cancer is the most advanced stage of breast cancer and is as yet incurable.  

The physical, psychological and emotional toll of metastatic breast cancer is considerable. 

For too long, women with metastatic breast cancer have been largely forgotten in the public discourse on breast cancer. Many feel ‘invisible’ within the breast cancer community, as there is such a strong focus on early detection and survival. Much can be done to improve the lives of women with metastatic breast cancer. 

Download project output

 

Metastatic breast cancer report

%

Breast cancer accounts for 29% of all new cancer diagnoses in women across Europe

%

20–30% of women initially diagnosed and treated for breast cancer will eventually develop metastatic breast cancer

Median survival for metastatic breast cancer is 2–3 years (although many women can live for much longer)

What we achieved

We created a number of reports in countries across the world, to raise awareness of this important type of breast cancer. Individual reports (country profiles) were created for Mexico, Israel and South Korea, along with regional reports for Asia, Latin America, Europe, and the Middle East and North Africa.

The reports convey key facts and figures regarding metastatic breast cancer and outline unmet needs in terms of public and professional awareness, management and care, and information and support services for women with metastatic breast cancer.

The Mexican country profile was launched publicly in August 2016. It has been endorsed by leading Mexican breast cancer patient organisations (Tómatelo a Pecho and Fundación CIMAB), the national association against cancer (Asociación Mexicana de Lucha contra el Cáncer) and the national cancer institute (Instituto Nacional de Cancerología).

Key partners and stakeholders (Mexican country profile)

  • Fundación CIMAB
  • Tómatelo a Pecho
  • Instituto Nacional de Cancerología (INCan)

The project was initiated and funded by Pfizer.